The evidence for pharmacologic treatment of neuropathic cancer pain: beneficial and adverse effects.


CONTEXT The prevalence of neuropathic pain in patients with cancer pain has been estimated to be around 40%. Neuropathic pain may be caused by tumor invasion and is considered as mixed nociceptive-neuropathic pain, or caused by an anticancer treatment and considered as purely neuropathic pain. The use of adjuvant analgesics in patients with cancer is… (More)
DOI: 10.1016/j.jpainsymman.2012.10.230


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics